New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
16:16 EDTTRGTTargacept reports Q4 EPS (47c), consensus (31c)
Reports Q4 revenue $590,000, consensus $830,000.
News For TRGT From The Last 14 Days
Check below for free stories on TRGT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
16:36 EDTTRGTTargacept discontinues TC-5214 development for overactive bladder
Targacept announced top-line results from a Phase 2b clinical trial of TC-5214 as a treatment for overactive bladder. In the trial, the high dose of TC-5214 demonstrated mixed results on the co-primary endpoints by providing a statistically significant reduction in micturition frequency and an improvement that did not reach statistical significance on episodes of urinary incontinence per 24 hours, after 12 weeks of treatment. As a consequence of these results, Targacept is discontinuing further development of TC-5214 in OAB. In this trial, TC-5214 was considered generally safe and well tolerated. However, there was a placebo corrected 15.1% rate of constipation and a 5.9% rate of urinary tract infection in the high dose group.
16:30 EDTTRGTTargacept trading halted, pending news
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use